Skip to content

In-Use Safety Evaluation to Determine the Dermal Irritation Potential and Consumer Perception of a Test Material

In-Use Safety Evaluation to Determine the Dermal Irritation Potential and Consumer Perception of a Test Material - In-Use Safety Evaluation to Determine the Dermal Irritation Potential and Consumer Perception of a Test Material

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000047965
Enrollment
35
Registered
2022-06-07
Start date
2022-05-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sensitive skin

Interventions

Apply the test material to inner forearms (right and left) and to shins (right and left) once a day for 4 weeks.

Sponsors

Lion Corporation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: a) Subject is male or female between 21 to 59 years of age (age and sex to be captured in the demographics); b) A subject exhibits no edema at baseline; c) Subject agrees not to introduce any new cosmetic or toiletry products during the study; d) Subject agrees not to use any itch relief products on the arms and legs for the duration of the study; e) Subject identifies as having self-perceived eczema prone skin; f) Subject has at least one of three conditions: significantly dry skin at a test site (2: mild to 3: moderate dry skin as determined by a board certified dermatologist), history of eczema, or history of atopic diathesis (skin condition and test site where skin condition is observed to be captured in the demographics); g) Subject agrees to refrain from tanning and swimming for the duration of the study; h) Subject agrees not to start a new exercise program for the duration of the study; i) Subject is dependable and able to follow directions as outlined in the protocol and usage instructions provided by the Sponsor; j) Subject is willing to participate in all study evaluations; k) Subject is in generally good health and has a current Panelist Profile Form on file at ECRL; l) Subject has completed a HIPAA Authorization Form in conformance with 45 CFR Parts 160 and 164; m) Subjects understands and is willing to sign an Informed Consent Form in conformance with 21 CRF Part 50: "Protection of Human Subjects."

Exclusion criteria

Exclusion criteria: a) Female subject (if applicable) is pregnant, nursing, planning a pregnancy, or not using adequate birth control; b) Subject has received treatment with sympathomimetics, antihistamines, vasoconstrictors, non-steroidal anti-inflammatory agents, and/or systemic or topical corticosteroids within one week prior to initiation of the study; c) Subject has a history of acute or chronic dermatologic, medical, and/or physical conditions which would preclude application of the test material and/or could influence the outcome of the study; d) Subject is currently taking certain medications which, in the opinion of the Principal Investigator, may interfere with the study; e) Subject has known allergies to skin treatment products or cosmetics, toiletries, and/or topical drugs; f) Subject has a history of skin cancer, or is currently undergoing treatment for active cancer of any kind; g) Subject has insulin-dependent diabetes.

Design outcomes

Primary

MeasureTime frame
Dermal evaluation by a dermatologist before and 4 weeks after use of a test material.

Countries

North America

Contacts

Public ContactAKINORI INOUE

Lion Corporation Global Development Center

ino-aki@lion.co.jp08012731828

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026